Showing results (71-80 of 82) with videos related to

Sort By:
Pageof 9
The Lancet. Oncology|August 13, 2021
Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trialJohann S de Bono, Niven Mehra, Giorgio V Scagliotti, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 8, 2023
Darolutamide Maintenance in Patients With Metastatic Castration-Resistant Prostate Cancer With Nonprogressive Disease After Taxane Treatment (SAKK 08/16)Silke Gillessen, Giuseppe Procopio, Stefanie Hayoz, et al.
Clinical Genitourinary Cancer|August 17, 2019
Quality-of-Life Assessment and Reporting in Prostate Cancer: Systematic Review of Phase 3 Trials Testing Anticancer Drugs Published Between 2012 and 2018Laura Marandino, Emmanuele De Luca, Clizia Zichi, et al.
European Journal of Cancer (Oxford, England : 1990)|August 9, 2021
Maintenance versus discontinuation of androgen deprivation therapy during continuous or intermittent docetaxel administration in castration-resistant prostate cancer patients: A multicentre, randomised Phase III study by the Piemonte Oncology NetworkSusanna Bianchi, Alessandra Mosca, Alberto Dalla Volta, et al.
Expert Review of Anticancer Therapy|November 5, 2021
Cabozantinib beyond progression improves survival in advanced renal cell carcinoma patients: the CABEYOND study (Meet-URO 21)Alessia Mennitto, Emma Zattarin, Massimo Di Maio, et al.
European Urology|October 4, 2021
Nivolumab in Combination with Stereotactic Body Radiotherapy in Pretreated Patients with Metastatic Renal Cell Carcinoma. Results of the Phase II NIVES StudyCristina Masini, Cinzia Iotti, Ugo De Giorgi, et al.
European Urology|March 23, 2024
Avelumab Plus Intermittent Axitinib in Previously Untreated Patients with Metastatic Renal Cell Carcinoma. The Tide-A Phase 2 StudyRoberto Iacovelli, Chiara Ciccarese, Sebastiano Buti, et al.
Clinical Genitourinary Cancer|October 5, 2023
TEAM Study: Upfront Docetaxel Treatment in Patients With Metastatic Hormone-Sensitive Prostate Cancer: A Real-World, Multicenter, Retrospective AnalysisChiara Pisano, Fabio Turco, Elena Arnaudo, et al.
Cancer Discovery|January 10, 2024
Noninvasive Detection of Neuroendocrine Prostate Cancer through Targeted Cell-free DNA MethylationGian Marco Franceschini, Orsetta Quaini, Kei Mizuno, et al.
European Urology|December 3, 2014
Clinical Outcomes of Castration-resistant Prostate Cancer Treatments Administered as Third or Fourth Line Following Failure of Docetaxel and Other Second-line Treatment: Results of an Italian Multicentre StudyOrazio Caffo, Ugo De Giorgi, Lucia Fratino, et al.
Pageof 9